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It has been one year since Brazil passed a law enabling scientists to work with human 
embryonic stem cells and to derive new stem cell lines from human embryos. But several 
major hurdles have put human embryonic stem cell research on hold.One year ago, the Brazilian House of 
Representatives finally approved the 
Biosafety Bill, which made it legal in 
Brazil to work with human embry-
onic stem cells (hESCs) and to derive 
hESC lines from surplus or nonviable 
human embryos stored for three or 
more years in IVF (in vitro fertiliza-
tion) clinics. Under the new law, no 
human embryo can be created for 
research purposes, and therapeutic 
cloning using somatic cell nuclear 
transfer is still forbidden. When the 
last vote on the Biosafety Bill was 
cast, the audience erupted into 
cheers as the result was announced: 
352 in favor of passing the law, 60 
against. Patients with muscular dys-
trophy joined hands with geneticist 
Mayana Zatz, a leading muscular 
dystrophy researcher, and with the 
Science and Technology Minister at 
that time, Eduardo Campos, to cel-
ebrate a landmark victory for Brazil’s 
scientific research community. After 
years of campaigning, scientists and 
patient advocates had obtained the 
right to produce and work with hESC 
lines in Brazil. However, one year 
after this encouraging victory, the 
applause has evaporated because 
not a single hESC colony has been 
derived so far. What are the reasons 
for this delay?
Within one month of the vote, 
the National Council for Scientific 
and Technological Development 
(better known by the old acronym 
CNPq), Brazil’s equivalent to the 
U.S. National Science Foundation, 
earmarked $5 million for stem cell 
research and published a call for cell 
therapy projects. Half of the funds 
were to come from the Science and 
Technology Ministry and half from 
the Health Ministry, which was eager to reap public health benefits from 
the new field of research, particularly 
as patient lobby groups had helped 
to get the Biosafety Bill passed.
The selection committee for the 
CNPq stem cell grants received 106 
proposals from research groups 
all over Brazil. However, only 41 
projects made it through to the next 
stage. The selection committee was 
composed of six biology researchers 
working at well-regarded institutions 
such as the University of São Paulo 
(USP) and the Federal University of 
Rio de Janeiro (UFRJ). The commit-
tee included Dr. Anibal Gil Lopes, 
which raised concerns in scientific 
circles because although Dr. Lopes 
is a respected researcher at UFRJ, he 
is also a Catholic priest and a mem-
ber of the Vatican’s Pontifical Acad-
emy Pro Vita. When the committee 
announced which projects would be 
funded at the end of August last year, 
CNPq found itself under heavy fire. 
Of the 41 projects funded, only three 
explicitly involved the study of ESCs 
and one of these was a proposal to 
grow rabbit (not human) ESCs on 
a substrate of iron nanoparticles to 
establish whether ESC colonies can 
be grown in the absence of mouse 
feeder cells.
Surprisingly, the proposal by 
Mayana Zatz of USP to derive 
hESC lines from human embryos 
was turned down, as was the pro-
posal by Lygia da Veiga Pereira, an 
experienced stem cell researcher 
also from USP and Zatz’s former 
collaborator. The feedback Pereira 
received from the selection commit-
tee filled a single line: “The proposal 
is plagued by lack of originality and 
does not show evidence of how the 
availability of those [hES] cells will Cell 124, Mbe able to impact breakthroughs in 
human health.” Says Pereira, “The 
result of the call for projects had 
disappointed many of us.”
José Eduardo Krieger at INCOR—
a renowned cardiology clinical 
research center linked to USP—also 
was dissatisfied with the selection 
committee’s initial decision not to 
fund his proposal to study the biol-
ogy of hESCs. He was particularly 
surprised about the absence of 
projects directed at the derivation 
of hESCs among the list of funded 
projects. “Such an important thing 
could never have been left out, since 
this is a key reagent in this area if we 
want to succeed in the development 
of new therapeutic approaches for 
adult organ repair.” Krieger received 
a similar response to his grant pro-
posal stating that although his 
project had merit the team had not 
enough expertise and experience to 
carry it out. Krieger, the head of the 
Genetics and Molecular Cardiology 
Lab at INCOR, was surprised by the 
allegation, given that his group had 
been chosen a few months earlier to 
run one of the four arms of a 1,200-
patient, $6 million clinical trial to treat 
cardiomyopathy with adult human 
bone marrow stem cells, sponsored 
by the very same ministries.
Zatz, Pereira, and Krieger, together 
with nine other principal investiga-
tors, appealed their decisions. The 
CNPq selection committee made 
public their final decision at the end 
of November last year: Four appeals 
were accepted, including those of 
the three USP research groups. Sub-
sequently, CNPq argued that the 
reversal was due solely to the new 
scientific arguments provided by the 
research groups that appealed, and arch 24, 2006 ©2006 Elsevier Inc. 1107
not to the controversy triggered by 
the first decision in August.
Given the difficulties surround-
ing the launch of hESC research 
in Brazil, Pereira and her collabo-
rator Stevens Rehen are spear-
heading an initiative to reach out 
to the private sector in the form of 
a Stem Cell Virtual Institute (IVCT, 
http://www.ivct.com.br). The idea 
behind this network of stem cell 
investigators is to attract private 
funds to finance the advancement 
of hESC research in Brazil, primarily 
through scientific collaborations and 
meetings, as well as through devel-
opment and dissemination of proto-
cols to promote standardization and 
to assure comparability of research 
outputs among laboratories through-
out the country. “IVCT will also pro-
vide an interface to discuss ethical 
issues and cellular therapies with 
physicians, the public, biotech com-
panies and the press in Brazil,” says 
Rehen. Thirty-five Brazilian laborato-
ries have expressed interest in join-
ing IVCT, whose Board is now in the 
process of uploading protocols and 
references onto the new website as 
well as information about plans to 
convene a meeting to discuss the first 
research results in a few months.
Meanwhile, hESC research in Brazil 
is facing another major hurdle. Clau-
dio Fonteles, in one of his last acts as 
Brazil’s Attorney General, brought a 
so-called “ação direta de inconstitu-
cionalidade” (direct unconstitution-
ality claim) against the Biosafety Law 
before the Federal Supreme Court 
in May last year. A devout Catholic, 
his petition argued that the permis-
sion to destroy human blastocysts 
to derive hESCs offended the basic 
constitutional tenet of life’s inviolabil-
ity: “The central thesis in the present 
claim is that human life happens in 
and starting with [the moment of] 
fertilization.” His successor, Anto-
nio Fernando Souza, supported the 
stance against hESCs in a brief to 
the Supreme Court dated November 
18, 2005. The constitutional issue is 
now under scrutiny by Justice Carlos 
Ayres Britto, who is expected to 
announce his decision in the next few 
weeks. It is widely believed that Britto 1108 Cell 124, March 24, 2006 ©2006 Elwill vote in favor of the Biosafety Law. 
However, a subsequent vote by the 
Plenum (a plenary session where at 
least 8 of the 11 Federal Supreme 
Court judges are present) is consid-
ered unpredictable.
Thus, hESC research in Brazil is 
standing on rather uncertain terrain. 
Colonies of hESCs received from 
laboratories outside of Brazil have 
just started to be unfrozen. Only in 
January this year, did CNPq begin 
to channel research money to the 
45 research groups whose projects 
had been approved. But even if the 
research money is flowing, the two 
USP projects that aim to derive hESC 
lines remain in jeopardy under the 
pending Supreme Court decision.
Although hESC research faces 
numerous roadblocks, research on 
adult stem cells continues to thrive in 
Brazil. Several clinical studies have 
yielded at least some successes 
using transplants of adult bone mar-
row stem cells to treat a host of dis-
eases from diabetes and cardiomy-
opathy to hepatic cirrhosis. One of 
the biggest clinical projects currently 
underway, funded by the Ministry of 
Health and the Ministry of Science 
and Technology, is to use adult bone 
marrow stem cells to treat cardio-
myopathies. More than 30 groups 
across the country are now part of 
the 1,200-patient Randomized Mul-
ticenter Study on Cellular Therapy in 
Cardiomyopathies (EMRTCC). There 
are four arms to the clinical trial—
patients with dilated cardiomyopa-
thy due to Chagas disease (a serious 
illness caused by a trypanosome 
parasite that is endemic in much of 
South America), and patients with 
general dilated cardiomyopathy, 
chronic ischemia, or acute myo-
cardial infarction. There are 300 
patients per arm: 150 will receive 
injections of autologous bone mar-
row stem cells into the heart, and 
150 will serve as the control group. 
The EMRTCC clinical trial follows 
preliminary safety studies with small 
numbers of patients, which showed 
that the procedure is safe.
In Brazil, clinical studies using 
adult stem cells are not overseen 
by ANVISA, the agency equivalent sevier Inc.to the FDA in the United States, 
because the injection of adult bone 
marrow stem cells into the heart is 
considered an extension of existing 
therapies. The sole requirement for 
this type of clinical study is approval 
from the National Council for Ethics 
in Research (CONEP).
About 100 patients have under-
gone the adult bone marrow stem 
cell injections so far, less than 10 
percent of the total 1,200. In spite of 
that, the Health Ministry boasts that 
Brazil is doing pioneer research and 
taking a leading role in the develop-
ment of stem cell therapies. Highly 
publicized estimates point to the 
goal of saving 200,000 lives over 
three years, once the technology is 
available, and saving $200 million 
annually in heart transplant costs. 
The work with adult stem cells has 
certainly proved an efficient way to 
gather public support for stem cell 
research in general. For instance, 
Brazil’s most popular weekly news 
magazine Veja portrayed stem cells 
on the cover of its November 23, 
2005 issue with the headline “The 
medicine that operates miracles.”
One pressing issue that needs 
to be addressed is the confusion 
among the general public regarding 
the difference between hESCs and 
adult stem cells, and how long it will 
be before either stem cell population 
is in routine clinical use. Krieger at 
INCOR considers that the nuanced 
differences between embryonic and 
adult stem cells have never been 
thoroughly laid out to the public. “It 
was a collective failure. I often talk to 
journalists, but have not been suffi-
ciently convincing, as those nuances 
have never made it to print.”
Several participants discussed 
this issue at the 1st Brazilian Meeting 
on Human Embryonic Stem Cells, in 
Rio de Janeiro in November of last 
year. Striking a cautionary note was 
Luiz Eugênio Mello, a neuroscientist 
with the Federal University of São 
Paulo (UNIFESP) and vice president 
of the Brazilian Federation of Experi-
mental Biology Societies (FeSBE). 
He hoped for expectations to be less 
“excessive” so as not to turn stem cell 
research into “another gene therapy,” 
by which he meant a glaring disap-
pointment in the eyes of the general 
public. His concern was echoed by 
Pereira. She regrets the wrong mes-
sage sent by the celebrations after 
the Biosafety Law was passed, which 
suggested that stem cell therapies 
were just around the corner.
Zatz, however, counters “All the 
patients who were there [in Con-
gress] knew perfectly well that we 
were defending the research. One 
has to consider that we deal with a 
population that has almost no degree 
of education, and maybe they think 
that we are going to inject hESCs 
and cure them immediately,” she says. “On the other hand, if we had 
not been very emphatic, perhaps we 
would not have won as we did.”
Not all Brazilian scientists are 
jumping on the stem cell bandwagon, 
however. Luiz Fernando Lima Reis, 
from the Ludwig Institute for Cancer 
Research and chair of the contro-
versial CNPq selection committee, 
would rather see more emphasis on 
basic research. “My personal belief 
is that Brazil, as any other country in 
the world, needs to investigate the 
biology of stem cells. I think there is 
hype and precipitation in the clinical 
use, or alleged clinical use, of stem 
cells. We don’t know yet the biology Cell 124, Mof these cells,” he said in an inter-
view. “There is an anxiety to treat 
people. We are cutting corners that 
are of major importance.”
With a final decision by the Federal 
Supreme Court expected shortly 
and funds beginning to flow from 
CNPq, Brazilian stem cell research 
should be able to take off at last. It 
remains to be seen whether initia-
tives such as IVCT will succeed in 
engaging the general public in the 
debate, such that societal support 
for this type of research can be 
based on solid information and not 
on unwarranted expectations about 
the powers of biomedicine.
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